Meeting
2023 ASCO Annual Meeting
Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
Authors
Emilie Le Rhun
University Hospital Zurich, Zurich, Switzerland
Emilie Le Rhun , Thierry Gorlia , Julia Furtner , Joerg Felsberg , Joost Jongen , Claude-Alain Maurage , Francois Ducray , Patrick Roth , Peter Hau , Olivier L. Chinot , Matthias Preusser , Stephanie Cartalat , Martin J. Van Den Bent , Maike Collienne , Guido Reifenberger , Michael Weller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03224104
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2054)
DOI
10.1200/JCO.2023.41.16_suppl.2054
Abstract #
2054
Poster Bd #
411
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis.
First Author: Michael Weller
Poster
2015 ASCO Annual Meeting
Phase I study of ABT-414 mono- or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM).
First Author: Hui K. Gan
Poster
2023 ASCO Annual Meeting
Phase I and pharmacodynamic study of arsenic trioxide plus radiotherapy for newly diagnosed glioblastoma.
First Author: Samuel Ryu
Poster
2022 ASCO Annual Meeting
Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
First Author: Louis B. Nabors